Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV.

ABSTRACT:

Purpose of review

To highlight mechanisms of elevated risk of atherosclerotic cardiovascular disease (ASCVD) among people living with HIV (PLWH), discuss therapeutic strategies, and opportunities for primary prevention.

Recent findings

HIV-associated ASCVD risk is likely multifactorial and due to HIV-specific factors and traditional risk factors even in the setting of treated and suppressed HIV disease. Although a growing body of evidence suggests that inflammation and immune activation are key drivers of atherogenesis, therapies designed to lower inflammation including colchicine and low-dose methotrexate have not improved secondary cardiovascular endpoints among PLWH. Statins continue to be the mainstay of management of hyperlipidemia in HIV, but the impact of newer lipid

SUBMITTER: Durstenfeld MS 

PROVIDER: S-EPMC8064238 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature